Becotatug Vedotin + Pucotenlimab+Platinum Induction and Sequential CCRT for Unresectable LA NSCLC

StatusNot Yet Recruiting
PhasePhase 2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
This is a prospective, single-arm phase II clinical study enrolling patients with locally advanced unresectable non-small cell lung cancer. All enrolled patients receive induction therapy with Becotatug Vedotin combined with pucotenlimab and platinum-based regimens. Patients who complete the scheduled induction treatment will subsequently receive definitive concurrent chemoradiotherapy.
Trial Details
NCT Number NCT07882940
Lead Sponsor Sun Yat-sen University
Conditions
(from sponsor)		 Non-Small Cell Carcinoma of Lung, Locally Advanced
Related terms Carcinoma, Non-Small-Cell Lung
Enrollment 24 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov